Journal article
Neutropenia as a Potential Pharmacodynamic Marker for Docetaxel-Based Chemotherapy in Men With Metastatic Castration-Resistant Prostate Cancer
Abstract
BACKGROUND: Docetaxel clearance appears increased in men who are castrated. Neutropenia in cycle 1 may be a pharmacodynamic marker for docetaxel, which may enable tailored dosing in metastatic castration-resistant prostate cancer (mCRPC).
PATIENTS AND METHODS: The association of cycle 1 neutropenia with overall survival (OS) was examined post hoc in a randomized phase II trial of 221 men with mCRPC who received docetaxel-prednisone combined …
Authors
Pond GR; Berry WR; Galsky MD; Wood BA; Leopold L; Sonpavde
Journal
Clinical Genitourinary Cancer, Vol. 10, No. 4, pp. 239–245
Publisher
Elsevier
Publication Date
12 2012
DOI
10.1016/j.clgc.2012.06.004
ISSN
1558-7673